PubMed:26684240 / 1538-1699 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"11022","span":{"begin":15,"end":19},"obj":"GeneOrGeneProduct"},{"id":"11023","span":{"begin":20,"end":25},"obj":"SequenceVariant"},{"id":"11024","span":{"begin":72,"end":81},"obj":"ChemicalEntity"},{"id":"11025","span":{"begin":143,"end":151},"obj":"DiseaseOrPhenotypicFeature"},{"id":"11026","span":{"begin":152,"end":160},"obj":"OrganismTaxon"}],"attributes":[{"id":"A52","pred":"db_id","subj":"11022","obj":"NCBIGene:673"},{"id":"A53","pred":"db_id","subj":"11023","obj":"DBSNP:rs113488022"},{"id":"A54","pred":"db_id","subj":"11024","obj":"MESH:C516667"},{"id":"A55","pred":"db_id","subj":"11025","obj":"MESH:C535650"},{"id":"A56","pred":"db_id","subj":"11026","obj":"NCBITaxon:9606"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients."}

{"project":"LitCoin-sentences","denotations":[{"id":"T10","span":{"begin":0,"end":161},"obj":"Sentence"}],"text":"In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients."}

{"project":"LitCoin-SeqVar","denotations":[{"id":"T5","span":{"begin":20,"end":25},"obj":"SequenceVariant"}],"text":"In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T34","span":{"begin":15,"end":19},"obj":"GeneOrGeneProduct"}],"text":"In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T68","span":{"begin":15,"end":19},"obj":"GeneOrGeneProduct"},{"id":"T69","span":{"begin":26,"end":34},"obj":"GeneOrGeneProduct"},{"id":"T70","span":{"begin":38,"end":44},"obj":"GeneOrGeneProduct"},{"id":"T71","span":{"begin":86,"end":94},"obj":"GeneOrGeneProduct"},{"id":"T72","span":{"begin":120,"end":128},"obj":"GeneOrGeneProduct"},{"id":"T73","span":{"begin":147,"end":151},"obj":"GeneOrGeneProduct"}],"text":"In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T30","span":{"begin":15,"end":19},"obj":"GeneOrGeneProduct"}],"text":"In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T15","span":{"begin":143,"end":151},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A15","pred":"ID:","subj":"T15","obj":"DISEASE"}],"text":"In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T15","span":{"begin":143,"end":151},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A15","pred":"#label","subj":"T15","obj":"DISEASE"}],"text":"In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T5","span":{"begin":72,"end":81},"obj":"ChemicalEntity"}],"attributes":[{"id":"A5","pred":"ID:","subj":"T5","obj":"C516667"},{"id":"A6","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_71219"}],"text":"In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T4","span":{"begin":152,"end":160},"obj":"OrganismTaxon"}],"text":"In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T5","span":{"begin":72,"end":81},"obj":"ChemicalEntity"},{"id":"T30","span":{"begin":15,"end":19},"obj":"GeneOrGeneProduct"},{"id":"T21549","span":{"begin":143,"end":151},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T14368","span":{"begin":152,"end":160},"obj":"OrganismTaxon"},{"id":"T53888","span":{"begin":20,"end":25},"obj":"SequenceVariant"}],"attributes":[{"id":"A6","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_71219"},{"id":"A5","pred":"ID:","subj":"T5","obj":"C516667"},{"id":"A15","pred":"#label","subj":"T21549","obj":"DISEASE"}],"text":"In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients."}